Literature DB >> 3852780

Characterization of monoclonal and polyclonal antibodies to human tissue kallikrein.

J Chao, L Chao, D M Tillman, C M Woodley, H S Margolius.   

Abstract

Monoclonal antibodies to purified human urinary kallikrein have been developed. Selection of antibody producing clones was based on 125I-kallikrein binding activity of hybridoma media in both radioimmunoassay and enzyme-linked immunosorbent assay. Three clones (2 IgG1, 1 IgG2b) were subcloned, characterized, and compared with the polyclonal antiserum generated in rabbits immunized with the purified kallikrein. With radioimmunoassay, mouse ascitic fluids or rabbit antisera dilutions showing 50% binding to 125I-kallikrein were 1:1.2 X 10(6) (E7A9), 1:1.2 X 10(5) (H6A6), 1:8.0 X 10(4) (E12H1), and 1:1.4 X 10(6) (the rabbit antisera). With enzyme-linked immunosorbent assay, mouse ascitic fluids from clones E7A9 and H6A6 showed half-maximal absorbance at dilutions of 1:2.1 X 10(5) and 1:1.0 X 10(5) respectively, and the polyclonal antiserum showed half-maximal absorbance at a dilution of 1:2.0 X 10(4). These monoclonal antibodies showed no cross-reactivity with rat tissue kallikrein, rat urinary plasminogen activator, or dog pancreatic kallikrein, while the polyclonal antiserum showed some cross-reactivity. The binding of monoclonal or polyclonal antibodies to 125I-human urinary kallikrein was not affected by human plasma kallikrein, thrombin, or urokinase in a competitive radioimmunoassay. By using purified human urinary kallikrein immobilized to agarose, antibodies produced by clones E7A9 and H6A6 and in the rabbit antisera were purified to homogeneity. Each of these affinity-purified antibodies inhibited the esterase activity, and two of the three inhibited the kininogenase activity, of human urinary kallikrein. A sandwich immunosorbent assay was developed to measure this kallikrein using monoclonal antibody from the clone E7A9 in conjunction with the polyclonal antibodies.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3852780     DOI: 10.1161/01.hyp.7.6.931

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  4 in total

1.  Expression and characterization of rat kallikrein-binding protein in Escherichia coli.

Authors:  J X Ma; L Chao; G Zhou; J Chao
Journal:  Biochem J       Date:  1993-06-15       Impact factor: 3.857

2.  Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats.

Authors:  C Wang; L Chao; J Chao
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

3.  Kallikrein-modified mesenchymal stem cell implantation provides enhanced protection against acute ischemic kidney injury by inhibiting apoptosis and inflammation.

Authors:  Makoto Hagiwara; Bo Shen; Lee Chao; Julie Chao
Journal:  Hum Gene Ther       Date:  2008-08       Impact factor: 5.695

4.  Tissue Kallikrein Activity, Detected by a Novel Method, May Be a Predictor of Recurrent Stroke: A Case-Control Study.

Authors:  Xiao Ran; Qin Zhang; Dao Wen Wang
Journal:  Dis Markers       Date:  2015-09-14       Impact factor: 3.434

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.